- Report
- August 2023
- 51 Pages
Germany
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
France
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
United States
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Australia
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Japan
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Turkey
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Italy
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
United Kingdom
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
China
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Switzerland
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Argentina
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Brazil
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Israel
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
Colombia
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
India
From €527EUR$600USD£458GBP
- Report
- August 2023
- 51 Pages
South Africa
From €527EUR$600USD£458GBP
- Report
- September 2024
- 150 Pages
Global
From €3379EUR$3,850USD£2,940GBP
€4257EUR$4,850USD£3,704GBP
- Report
- October 2025
- 82 Pages
Vietnam
From €4257EUR$4,850USD£3,704GBP
- Report
- October 2025
- 90 Pages
Kuwait
From €4257EUR$4,850USD£3,704GBP
- Report
- October 2025
- 99 Pages
Philippines
From €4257EUR$4,850USD£3,704GBP

The CRISPR market is a subset of the genomics market that focuses on the use of CRISPR-Cas9 technology for gene editing. CRISPR-Cas9 is a powerful tool that enables scientists to make precise changes to the genome of living organisms. This technology has been used to develop treatments for a variety of diseases, as well as to create new crops and livestock. CRISPR-Cas9 technology has also been used to create gene drives, which are designed to spread a desired trait through a population.
The CRISPR market is highly competitive, with a number of companies offering products and services related to gene editing. These companies include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, and ERS Genomics. These companies are developing a range of products, from gene editing tools to gene therapies, and are working to make CRISPR-Cas9 technology more accessible and affordable. Show Less Read more